Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Francesca Re

Showing results (101-110 of 115) with videos related to

Pageof 12
Sort By:
Leukemia & Lymphoma|March 8, 2025
A phase 2 study of autologous stem cell transplantation as salvage therapy for older patients with aggressive B-cell lymphoma prospectively evaluated by comprehensive geriatric assessment: the FIL_RECANZ studyAlessandra Tucci, Alessandro Re, Chiara Pagani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 22, 2019
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent LymphomaJohn P Leonard, Marek Trneny, Koji Izutsu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2022
Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana LinfomiMichele Merli, Sara Rattotti, Michele Spina, et al.
Blood|July 12, 2019
Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 studyStefano Luminari, Michele Merli, Sara Rattotti, et al.
Scientific Reports|July 23, 2024
Stem cell collection and hematological recovery in the Fondazione Italiana Linfomi (FIL) MCL0208 clinical trialMichele Clerico, Simone Ferrero, Beatrice Alessandria, et al.
Blood|June 23, 2022
Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphomaSimone Ferrero, Daniele Grimaldi, Elisa Genuardi, et al.
Hematological Oncology|May 29, 2023
Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naïve advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana LinfomiMaria E Nizzoli, Martina Manni, Chiara Ghiggi, et al.
British Journal of Haematology|November 9, 2018
Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 studyEmilio Iannitto, Monica Bellei, Sandy Amorim, et al.
The Lancet. Haematology|January 29, 2021
MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trialAndrés J M Ferreri, Jeanette K Doorduijn, Alessandro Re, et al.
Eclinicalmedicine|April 18, 2024
Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatmentLuca Arcaini, Côme Bommier, Juan Pablo Alderuccio, et al.
Pageof 12

Showing results (101-110 of 115) with videos related to

Sort By:
Pageof 12
Leukemia & Lymphoma|March 8, 2025
A phase 2 study of autologous stem cell transplantation as salvage therapy for older patients with aggressive B-cell lymphoma prospectively evaluated by comprehensive geriatric assessment: the FIL_RECANZ studyAlessandra Tucci, Alessandro Re, Chiara Pagani, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 22, 2019
AUGMENT: A Phase III Study of Lenalidomide Plus Rituximab Versus Placebo Plus Rituximab in Relapsed or Refractory Indolent LymphomaJohn P Leonard, Marek Trneny, Koji Izutsu, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|June 17, 2022
Direct-Acting Antivirals as Primary Treatment for Hepatitis C Virus-Associated Indolent Non-Hodgkin Lymphomas: The BArT Study of the Fondazione Italiana LinfomiMichele Merli, Sara Rattotti, Michele Spina, et al.
Blood|July 12, 2019
Early progression as a predictor of survival in marginal zone lymphomas: an analysis from the FIL-NF10 studyStefano Luminari, Michele Merli, Sara Rattotti, et al.
Scientific Reports|July 23, 2024
Stem cell collection and hematological recovery in the Fondazione Italiana Linfomi (FIL) MCL0208 clinical trialMichele Clerico, Simone Ferrero, Beatrice Alessandria, et al.
Blood|June 23, 2022
Punctual and kinetic MRD analysis from the Fondazione Italiana Linfomi MCL0208 phase 3 trial in mantle cell lymphomaSimone Ferrero, Daniele Grimaldi, Elisa Genuardi, et al.
Hematological Oncology|May 29, 2023
Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naïve advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana LinfomiMaria E Nizzoli, Martina Manni, Chiara Ghiggi, et al.
British Journal of Haematology|November 9, 2018
Efficacy of bendamustine and rituximab in splenic marginal zone lymphoma: results from the phase II BRISMA/IELSG36 studyEmilio Iannitto, Monica Bellei, Sandy Amorim, et al.
The Lancet. Haematology|January 29, 2021
MATRix-RICE therapy and autologous haematopoietic stem-cell transplantation in diffuse large B-cell lymphoma with secondary CNS involvement (MARIETTA): an international, single-arm, phase 2 trialAndrés J M Ferreri, Jeanette K Doorduijn, Alessandro Re, et al.
Eclinicalmedicine|April 18, 2024
Marginal zone lymphoma international prognostic index: a unifying prognostic index for marginal zone lymphomas requiring systemic treatmentLuca Arcaini, Côme Bommier, Juan Pablo Alderuccio, et al.
Pageof 12